Evidence map›Paper›PMID 37639653›Full record

ArticleJCO clinical cancer informatics2023

Development of an Electronic Health Record-Based Clinical Decision Support Tool for Patients With Lynch Syndrome.

Kelsey S Lau-Min, Joseph Bleznuck, Colin Wollack, Danielle B McKenna, Jessica M Long, Anna P Hubert, Mariah Johnson, Shavon E Rochester, Gillain Constantino, Christina Dudzik and 7 more

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2026
    Article
  5. Oncology nurses' readiness to implement genomics-informed care: A descriptive, cross-sectional study in a Canadian province.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2026
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kelsey S Lau-MinDivision of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0001-8854-224X
Joseph BleznuckInformation Services Applications, Penn Medicine, University of Pennsylvania, Philadelphia, PA.
Colin WollackInformation Services Applications, Penn Medicine, University of Pennsylvania, Philadelphia, PA.
Danielle B McKennaDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-8317-1520
Jessica M LongDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0003-0382-7890
Anna P HubertDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0009-0001-6319-3108
Mariah JohnsonDepartment of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Shavon E RochesterDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Gillain ConstantinoDivision of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-7997-7572
Christina DudzikDivision of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-5485-9804
Abigail DoucetteDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-6646-433X
Kirk WangensteenDivision of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6042-6490
Susan M DomchekDivision of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-5914-7272
Jeffrey LandgrafInformation Services Applications, Penn Medicine, University of Pennsylvania, Philadelphia, PA.
Jessica ChenInformation Services Applications, Penn Medicine, University of Pennsylvania, Philadelphia, PA.
Katherine L NathansonDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-6740-0901
Bryson W KatonaDivision of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-8186-9119

Funding

Randomized trial of universal vs. guideline-directed germline testing among young adults with cancerU01CA232836 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JOFFE, STEVEN, NATHANSON, KATHERINE L. · 2019 to 2022
$5.0M
Postdoctoral Training Program in Genomic MedicineT32HG009495 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI Katherine L. Nathanson, Bogdan Pasaniuc · 2017 to 2026
$4.2M
NCI NIH HHS U01 CA232836NHGRI NIH HHS T32 HG009495
6 · The paper itself

Abstract

purposeTo develop an electronic health record (EHR)-based clinical decision support (CDS) tool to promote guideline-recommended cancer risk management among patients with Lynch syndrome (LS), an inherited cancer syndrome that confers an increased risk of colorectal and other cancer types. MATERIALS AND

methodsWe conducted a cross-sectional study to determine the baseline prevalence and predictors of guideline-recommended colonic surveillance and annual genetics program visits among patients with LS. Multivariable log-binomial regressions estimated prevalence ratios (PRs) of cancer risk management adherence by baseline sociodemographic and clinical characteristics. These analyses provided rationale for the development of an EHR-based CDS tool to support patients and clinicians with LS-related endoscopic surveillance and annual genetics program visits. The CDS leverages an EHR platform linking discrete genetic data to LS Genomic Indicators, in turn driving downstream clinician- and patient-facing CDS.

resultsAmong 323 patients with LS, cross-sectional adherence to colonic surveillance and annual genetics program visits was 69.3% and 55.4%, respectively. Patients with recent electronic patient portal use were more likely to be adherent to colonic surveillance (PR, 1.67; 95% CI, 1.11 to 2.52). Patients more recently diagnosed with LS were more likely to be adherent to annual genetics program visits (PR, 0.58; 95% CI, 0.44 to 0.76 for 2-4 years; PR, 0.62; 95% CI, 0.51 to 0.75 for ≥4 compared with <2 years). Our EHR-based CDS tool is now active for 421 patients with LS throughout our health system.

conclusionWe have successfully developed an EHR-based CDS tool to promote guideline-recommended cancer risk management among patients with LS.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisDecision Support Systems, ClinicalCross-Sectional StudiesElectronic Health RecordsElectronicsHumans

Identifiers

PMID37639653
PMCPMC10857752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.